Bacillus calmette-guerin versus chemotherapy for the intravesical treatment of patients with carcinoma in situ of the bladder: a meta-analysis of the published results of randomized clinical trials.

No abstract is available for this paper.

• Publication year

  2005

• Venue

  Journal of Urology

• Publication date

  2005-07-01

• Fields of study

  Medicine

• Identifiers
  DOI 10.1097/01.JU.0000162059.64886.1CPMID 15947584
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Bacillus Calmette-Guerin versus epirubicin for primary, secondary or concurrent carcinoma in situ of the bladder: results of a European Organization for the Research and Treatment of Cancer--Genito-Urinary Group Phase III Trial (30906).

  2005cited by this paper
• 1497: Use of Propsa within Artificial Neural Networks to Improve Prostate Cancer Specificity

  2005cited by this paper
• Re: Bacillus Calmette-Guerin versus epirubicin for primary, secondary or concurrent carcinoma in situ of the bladder: results of a European Organization for the Research and Treatment of Cancer-Genito-Urinary Group Phase III Trial (30906).

  2005cited by this paper
• Intravesical bacillus Calmette‐Guérin is superior to mitomycin C in reducing tumour recurrence in high‐risk superficial bladder cancer: a meta‐analysis of randomized trials

  2004cited by this paper
• Intravesical bacille Calmette-Guérin versus mitomycin C in superficial bladder cancer: formal meta-analysis of comparative studies on tumor progression.

  2004cited by this paper
• Intravesical electromotive mitomycin C versus passive transport mitomycin C for high risk superficial bladder cancer: a prospective randomized study.

  2003influential reference
• Intravesical bacillus Calmette-Guerin versus mitomycin C for superficial bladder cancer: a formal meta-analysis of comparative studies on recurrence and toxicity.

  2003cited by this paper
• Maintenance Bacillus Calmette-Guerin for Ta T1 bladder tumors is not associated with increased toxicity: results from a European Organisation for Research and Treatment of Cancer Genito-Urinary Group Phase III Trial.

  2003cited by this paper
• Intravesical bacillus Calmette-Guerin reduces the risk of progression in patients with superficial bladder cancer: a meta-analysis of the published results of randomized clinical trials.

  2002cited by this paper
• Equivalent efficacy of mitomycin C plus doxorubicin instillation to bacillus Calmette‐Guerin therapy for carcinoma in situ of the bladder

  2001cited by this paper
• Maintenance bacillus Calmette-Guerin immunotherapy for recurrent TA, T1 and carcinoma in situ transitional cell carcinoma of the bladder: a randomized Southwest Oncology Group Study.

  2000cited by this paper
• Treatment of Superficial Bladder Tumors: Achievements and Needs

  2000cited by this paper
• 5-year followup of a randomized prospective study comparing mitomycin C and bacillus Calmette-Guerin in patients with superficial bladder carcinoma. Swedish-Norwegian Bladder Cancer Study Group.

  1999cited by this paper
• Long-Term Follow-Up of an EORTC Randomized Prospective Trial Comparing Intravesical Bacille Calmette-Guerin-RIVM and Mitomycin C in Superficial Bladder Cancer

  1999cited by this paper
• The World Health Organization/International Society of Urological Pathology consensus classification of urothelial (transitional cell) neoplasms of the urinary bladder. Bladder Consensus Conference Committee.

  1998cited by this paper
• The World Health Organization/International Society of Urological Pathology consensus classification of urothelial (transitional cell) neoplasms of the urinary bladder

  1998cited by this paper
• Long-term follow-up of an EORTC randomized prospective trial comparing intravesical bacille Calmette-Guérin-RIVM and mitomycin C in superficial bladder cancer. EORTC GU Group and the Dutch South East Cooperative Urological Group. European Organisation for Research and Treatment of Cancer Genito-Urin

  1998cited by this paper
• Results of a randomized phase III trial of sequential intravesical therapy with mitomycin C and bacillus Calmette-Guerin versus mitomycin C alone in patients with superficial bladder cancer.

  1998cited by this paper
• Updated concepts and treatment of carcinoma in situ.

  1998influential reference
• Randomized intergroup comparison of bacillus calmette-guerin immunotherapy and mitomycin C chemotherapy prophylaxis in superficial transitional cell carcinoma of the bladder a southwest oncology group study.

  1995cited by this paper
• Alternating mitomycin C and bacillus Calmette-Guerin instillation therapy for carcinoma in situ of the bladder. The Finnbladder Group.

  1995cited by this paper
• Original Articles: Bladder Cancer

  1995cited by this paper
• Intravesical 4′‐epi‐doxorubicin(epirubicin) versus bacillus calmette—guérin. A controlled prospective study on the prophylaxis of superficial bladder cancer

  1993cited by this paper
• A Southwest Oncology Group study

  1993cited by this paper
• Meta-analysis: the fashion of summing-up evidence. Part II: Interpretations and uses.

  1992cited by this paper
• Meta-analysis: the fashion of summing-up evidence. Part I. Rationale and conduct.

  1991cited by this paper
• Intravesical chemotherapy (mitomycin C) versus immunotherapy (bacillus Calmette-Guérin) in superficial bladder cancer.

  1991cited by this paper
• A randomized trial of intravesical doxorubicin and immunotherapy with bacille Calmette-Guérin for transitional-cell carcinoma of the bladder.

  1991cited by this paper
• Bacillus Calmette-Guerin versus doxorubicin versus thiotepa: a randomized prospective study in 202 patients with superficial bladder cancer.

  1990influential reference
• Cross-sectional imaging of multilocular cystic nephroma.

  1982cited by this paper
• Experience with bacillus Calmette-Guerin in patients with superficial bladder carcinoma.

  1982cited by this paper
• Carcinoma in situ of the bladder

  1971cited by this paper

• Budget impact model of nadofaragene firadenovec for the treatment of high-risk non-muscle-invasive bladder cancer that is unresponsive to Bacillus Calmette-Guérin immunotherapy.

  2026cites this paper
• Targeting Bladder Cancer with Inactivated Uropathogenic E. coli: A Novel Alternative to BCG Immunotherapy

  2026cites this paper
• Prognostic factors for the recurrence, progression, and multiple recurrences of non-muscle-invasive bladder cancer in Eastern Taiwan

  2025cites this paper
• Intravesical BCG: A Double-Edged Sword? The Untold Story of Infection Risks

  2025cites this paper
• Durvalumab in combination with BCG for BCG-naive, high-risk, non-muscle-invasive bladder cancer (POTOMAC): final analysis of a randomised, open-label, phase 3 trial.

  2025cites this paper
• Combination regimen of intravesical docetaxel, gemcitabine, and cisplatin in patients with BCG-unresponsive bladder cancer: clinical outcomes and genomic correlations.

  2025cites this paper
• Infection of the acromioclavicular joint with Mycobacterium bovis following intravesical instillation of Bacillus Calmette-Guerin: a case-based review

  2025cites this paper
• Immunotherapies to Nano-Immunotherapies: Advances in Immune Targeting in Bladder Cancer

  2025cites this paper
• BCGitis: Absceso pélvico por Mycobacterium bovis BCG posterior a inmunoterapia en cáncer de vejiga. Reporte de un caso

  2025cites this paper
• Review of BCG immunotherapy for bladder cancer

  2025cites this paper
• Development of TAR-200: A novel targeted releasing system designed to provide sustained delivery of gemcitabine for patients with bladder cancer.

  2025cites this paper
• A Rare Case of Hemophagocytic Lymphohistiocytosis Triggered by Intravesical Bacillus Calmette-Guérin (BCG) for Bladder Cancer

  2025cites this paper
• Exploring the Immunoresponse in Bladder Cancer Immunotherapy

  2024cites this paper
• Retrospective, Non-Interventional, Multicenter Study on the Effectiveness and Safety of Intravesical Bacillus Calmette–Guerin in Patients with Non-Muscle-Invasive Bladder Cancer: Real-World Experience from Six Hospital Centers in Greece

  2024cites this paper
• European Association of Urology Guidelines on Non-muscle-invasive Bladder Cancer (TaT1 and Carcinoma In Situ)-A Summary of the 2024 Guidelines Update.

  2024cites this paper
• Drug repurposing for cancer.

  2024cites this paper
• Redox System and Oxidative Stress-Targeted Therapeutic Approaches in Bladder Cancer

  2024cites this paper
• Myeloid-Derived Suppressor Cells in Bladder Cancer: An Emerging Target

  2024cites this paper
• Neue Therapieansätze beim nicht-muskelinvasiven Urothelkarzinom der Harnblase – Ist der Organerhalt auch nach BCG (Bacillus Calmette-Guérin) möglich?

  2024cites this paper
• Comment prescrire des instillations intra-vésicales de Gemcitabine et Docétaxel ?

  2024cites this paper
• Refinement of Risk Stratification Is Important for Guiding Treatment and Surveillance Recommendations.

  2024cites this paper
• Preoperative blood-based nutritional biomarkers as significant prognostic factors after intravesical BCG therapy in patients with non-muscle-invasive bladder cancer

  2024cites this paper
• Microbiome-based Therapeutics: Cutting-edge Innovation.

  2024cites this paper
• Revitalizing Bacillus Calmette–Guérin Immunotherapy for Bladder Cancer: Nanotechnology and Bioengineering Approaches

  2024cites this paper
• Bacillus Calmette-Guérin (BCG)-Induced Protection in Brain Disorders

  2024influential citation
• Safety and Efficacy of Immediate Hyperthermic Intravesical Chemotherapy Following Transurethral Resection of Bladder Tumour (I-HIVEC).

  2024cites this paper
• The role of TERT C228T and KDM6A alterations and TME in NMIBC treated with BCG

  2024influential citation
• Optimizing outcomes and managing adverse events in locally advanced or metastatic urothelial cancer: a clinical pharmacology perspective

  2023cites this paper
• Novel immunotherapeutic options for BCG‐unresponsive high‐risk non‐muscle‐invasive bladder cancer

  2023cites this paper
• Knowledge-map analysis of bladder cancer immunotherapy

  2023cites this paper
• Role of Basic Fibroblast Growth Factor in Cancer: Biological Activity, Targeted Therapies, and Prognostic Value

  2023cites this paper
• Haemophagocytic lymphohistiocytosis after intravesical BCG administration for bladder cancer presenting with multiorgan failure

  2023cites this paper
• Prognostic Significance of HER2 Expression in Patients with Bacillus Calmette-Guérin-exposed Non-muscle-invasive Bladder Cancer.

  2023cites this paper
• Implications of Toll-like receptors (TLRs) and their signaling mechanisms in human cancers.

  2023cites this paper
• [Evaluation of the efficacy and safety of HIVEC intravesical thermochemotherapy with intermediate-risk and high-risk non-muscle-invasive bladder cancer].

  2023cites this paper
• Targeting microRNA-145-mediated progressive phenotypes of early bladder cancer in a molecularly defined in vivo model

  2023cites this paper
• Adjuvant therapies for non-muscle-invasive bladder cancer: advances during BCG shortage

  2022cites this paper
• Bibliometric analysis of the 100 top-cited articles on immunotherapy of urological cancer

  2022cites this paper
• New Perspectives in the Medical Treatment of Non-Muscle-Invasive Bladder Cancer: Immune Checkpoint Inhibitors and Beyond

  2022cites this paper
• First American Cancer Patient to Receive Dicycloplatin (DCP) Chemotherapy Achieves Remission After Seven Weeks of DCP Capsules – A Case Report

  2022cites this paper
• Bladder tuberculosis with ureteral strictures after bacillus Calmette‑Guérin therapy for urinary bladder cancer: A case report

  2022cites this paper
• A Multicenter Study of 2-year Outcomes Following Hyperthermia Therapy with Mitomycin C in Treating Non-Muscle Invasive Bladder Cancer: HIVEC-E

  2022cites this paper
• Preoperative systemic inflammation response index is an independent prognostic marker for BCG immunotherapy in patients with non‐muscle‐invasive bladder cancer

  2022cites this paper
• Impact of Finasteride on Survival in Bladder Cancer: A Retrospective Multi-institutional Database Analysis.

  2022cites this paper
• Enhancement of human bladder carcinoma cell chemosensitivity to Mitomycin C through quasi-monochromatic blue light (λ = 453 ± 10 nm).

  2022cites this paper
• Pharmacologic Therapies for Non-Muscle Invasive Bladder Cancer: Current and Future Treatments

  2022cites this paper
• NCCN Guidelines® Insights: Bladder Cancer, Version 2.2022.

  2022cites this paper
• Real‐world treatment patterns and oncological outcomes in early relapse and refractory disease after bacillus Calmette‐Guérin failure in non‐muscle‐invasive bladder cancer

  2022cites this paper
• [BCG-therapy as a rare reason for postrenal failure].

  2022cites this paper
• The Urinary Microbiome: Role in Bladder Cancer and Treatment

  2022cites this paper
• The Factors Affecting Expansion of Reactive Tumor Infiltrating Lymphocytes (TIL) From Bladder Cancer and Potential Therapeutic Applications

  2021cites this paper
• Canadian Urological Association guideline on the management of non-muscle invasive bladder cancer.

  2021cites this paper
• Thulium Laser Resection of Bladder Tumors vs. Conventional Transurethral Resection of Bladder Tumors for Intermediate and High Risk Non-Muscle-Invasive Bladder Cancer Followed by Intravesical BCG Immunotherapy

  2021cites this paper
• Early Photodynamic Diagnosis Cystoscopy After Bacillus Calmette–Guérin (BCG) Induction for High-Risk Nonmuscle Invasive Bladder Cancer Significantly Increased the Detection of BCG Refractory Tumors

  2021cites this paper
• First Brazilian consensus on the management of localized and locally advanced urothelial bladder cancer: a SBU-SBOC-SBRT-LACOG-GU panel review

  2021cites this paper
• Canadian Urological Association guideline on the management of non-muscle-invasive bladder cancer - Abridged version.

  2021cites this paper
• Adjuvant Intravesical Therapy: Bacillus Calmette-Guerin

  2021cites this paper
• A trial of intra-pleural bacterial immunotherapy in malignant pleural mesothelioma (TILT) — a randomised feasibility study using the trial within a cohort (TwiC) methodology

  2021cites this paper
• Novel and emerging approaches in the management of non-muscle invasive urothelial carcinoma

  2021cites this paper
• European Association of Urology Guidelines on Non-muscle-invasive Bladder Cancer (Ta, T1, and Carcinoma in Situ).

  2021cites this paper
• [OUTCOMES OF BLADDER CANCER IN NONAGENARIANS].

  2021cites this paper
• Immunostimulatory Response of RWFV Peptide-Targeted Lipid Nanoparticles on Bladder Tumor Associated Cells.

  2021cites this paper
• Current Therapy and Emerging Intravesical Agents to Treat Non-Muscle Invasive Bladder Cancer.

  2021cites this paper
• Efficacy of Intra-Arterial Plus Intravesical Chemotherapy for High-Risk Non-Muscle-Invasive Bladder Cancer: A Pooled Analysis

  2021cites this paper
• Impact of clinical and pathological subtypes of carcinoma in situ (CIS) of the bladder: Lessons learned from long-term follow-up of a series of CIS patients treated with BCG.

  2021cites this paper
• Quality Indicators for Bladder Cancer Services: A Collaborative Review.

  2020cites this paper
• Bladder Cancer: A Review.

  2020cites this paper
• Immunotherapy in Bacillus Calmette-Guerin (BCG) unresponsive nonmuscle invasive bladder cancer.

  2020influential citation
• Carcinoma In Situ of the Urinary Bladder: A Systematic Review of Current Knowledge Regarding Detection, Treatment, and Outcomes.

  2020cites this paper
• Efficacy of intravesical therapies on the prevention of recurrence and progression of non‐muscle‐invasive bladder cancer: A systematic review and network meta‐analysis

  2020cites this paper
• Combination of novel intravesical xenogeneic urothelial cell immunotherapy and chemotherapy enhances anti-tumor efficacy in preclinical murine bladder tumor models

  2020cites this paper
• The Role of Fluorescence in Situ Hybridization for Predicting Recurrence after Adjuvant Bacillus Calmette-Guérin in Intermediate- and High-Risk Non-muscle Invasive Bladder Cancer Patients: A Systematic Review and Meta-Analysis of Individual Patient Data.

  2020cites this paper
• Bladder cancer.

  2020cites this paper
• Disseminated BCG sepsis following intravesical therapy for Bladder Carcinoma: A case report and review of literature

  2020cites this paper
• Trained immunity as a molecular mechanism for BCG immunotherapy in bladder cancer

  2020cites this paper
• Bladder Cancer

  2020cites this paper
• Carcinoma in situ of the bladder: why is it underdetected?

  2020cites this paper
• Breast Cancer, Version 3.2020, NCCN Clinical Practice Guidelines in Oncology.

  2020cites this paper
• Salvage Therapy for Non-muscle-invasive Bladder Cancer: Novel Intravesical Agents.

  2020cites this paper
• Bacillus Calmette-Guérin Salvage Therapy: Definitions and Context.

  2020cites this paper
• The Tumor Microenvironment of Bladder Cancer.

  2020cites this paper
• Bladder Cancer

  2020cites this paper
• Immunotherapy in Bladder and Renal Cancers

  2020cites this paper
• A prospective comparative study to assess the efficacy and tolerability of 2 different doses of intravesical bacillus Calmette-Guerin (BCG) in patients with non-muscle-invasive bladder cancer.

  2020cites this paper
• Immunotherapy in Bladder Cancer: Current Methods and Future Perspectives

  2020cites this paper
• Intravesical BCG: where do we stand? Past, present and future

  2019cites this paper
• INHIBITION OF UROTHELIAL CARCINOMA BY TYPE I INTERFERON ACTIVATION OF THE INNATE AND ADAPTIVE IMMUNE RESPONSE

  2019cites this paper
• Intravesical Therapy – BCG and Beyond

  2019influential citation
• Percutaneous BCG enhances innate effector antitumor cytotoxicity during treatment of bladder cancer: a translational clinical trial

  2019cites this paper
• EFFECTIVENESS OF SINGLE DOSE INTRAVESICAL MITOMYCIN C THERAPY AS PROPHYLAXIS TO PREVENT RECURRENCE AND PROGRESSION OF SUPERFICIAL NONMUSCLE INVASIVE BLADDER TUMOR.

  2019cites this paper
• EAU Guidelines pro léčbu uroteliálního karcinomu močového měchýře , který neinvaduje svalovinu – aktualizovaná verze z roku 2011

  2019cites this paper
• Intrinsic cancer vaccination.

  2019cites this paper
• European Association of Urology Guidelines on Non-muscle-invasive Bladder Cancer (TaT1 and Carcinoma In Situ) - 2019 Update.

  2019cites this paper
• Bacillus Calmette–Guérin immunotherapy for bladder cancer: a review of immunological aspects, clinical effects and BCG infections

  2019influential citation
• Bacillus Calmette-Guérin Cases Reported to the National Tuberculosis Surveillance System, United States, 2004–2015

  2019cites this paper
• Multi-Perspective Tolerance Evaluation of Bacillus Calmette-Guerin with Interferon in the Treatment of Non-Muscle Invasive Bladder Cancer

  2019cites this paper
• Intercellular transfer of P-glycoprotein mediates the formation of stable multi-drug resistance in human bladder cancer BIU-87 cells

  2019cites this paper
• How to Treat a Patient with T1 High-grade Disease and No Tumour on Repeat Transurethral Resection of the Bladder?

  2019cites this paper
• Identification of Neoantigen-Reactive Tumor-Infiltrating Lymphocytes in Primary Bladder Cancer

  2019influential citation
• Are intra-pleural bacterial products associated with longer survival in adults with malignant pleural effusions? A systematic review.

  2018cites this paper